Literature DB >> 29449425

Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study.

Yunus Çolak1,2, Shoaib Afzal1,2, Børge G Nordestgaard1,2,3, Jørgen Vestbo4, Peter Lange2,3,5,6.   

Abstract

A presumed consequence of using a fixed ratio for the definition of airflow limitation (AFL) has been overdiagnosis among older individuals and underdiagnosis among younger individuals. However, the prognosis of younger individuals with potentially underdiagnosed AFL is poorly described. We hypothesised that potential underdiagnosis of AFL at a younger age is associated with poor prognosis.We assigned 95 288 participants aged 20-100 years from the Copenhagen General Population Study into the following groups: individuals without AFL with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ≥0.70 and ≥lower limit of normal (LLN) (n=78 779, 83%); individuals with potentially underdiagnosed AFL with FEV1/FVC ≥0.70 and <LLN (n=1056, 1%); individuals with potentially overdiagnosed AFL with FEV1/FVC <0.70 and ≥LLN (n=3088, 3%); and individuals with AFL with FEV1/FVC <0.70 and <LLN (n=12 365, 13%). We assessed risk of exacerbations, pneumonias, ischaemic heart disease, heart failure and all-cause mortality. Median follow-up was 6.0 years (range: 2 days-11 years).Compared to individuals without AFL, individuals with potentially underdiagnosed AFL had an increased risk of morbidity and mortality with age- and sex-adjusted hazard ratios (HR) of 2.7 (95% CI: 1.7-4.5) for pneumonias, 2.3 (95% CI: 1.2-4.5) for heart failure, and 3.1 (95% CI: 2.1-4.6) for all-cause mortality.Young and middle-aged adults with AFL according to LLN but not fixed ratio experience increased respiratory and cardiovascular morbidity and early death.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29449425     DOI: 10.1183/13993003.02681-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

1.  Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Authors:  Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Patricia A Cassano; David Couper; David R Jacobs; Ravi Kalhan; George T O'Connor; Sachin Yende; Jason L Sanders; Jason G Umans; Mark T Dransfield; Paulo H Chaves; Wendy B White; Elizabeth C Oelsner
Journal:  JAMA       Date:  2019-06-25       Impact factor: 56.272

2.  Highlights from the European Respiratory Society 2018 Annual Congress: environment and epidemiology (assembly 6).

Authors:  André F S Amaral
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

3.  Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.

Authors:  Yunus Çolak; Shoaib Afzal; Børge G Nordestgaard; Jørgen Vestbo; Peter Lange
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

Review 4.  Advances in Chronic Obstructive Pulmonary Disease.

Authors:  Michael C Ferrera; Wassim W Labaki; MeiLan K Han
Journal:  Annu Rev Med       Date:  2021-01-27       Impact factor: 13.739

5.  Phenotypic Heterogeneity in Chronic Obstructive Pulmonary Disease.

Authors:  Malvika Kaul; Solomon Krow; Ai-Yui M Tan; Sunit Singla
Journal:  Am J Respir Crit Care Med       Date:  2022-01-01       Impact factor: 21.405

Review 6.  Impaired Respiratory Health and Life Course Transitions From Health to Chronic Lung Disease.

Authors:  Gabrielle Y Liu; Ravi Kalhan
Journal:  Chest       Date:  2021-04-15       Impact factor: 10.262

7.  Predictors of accelerated FEV1 decline in adults with airflow limitation-Findings from the Health2006 cohort.

Authors:  Camilla Boslev Baarnes; Betina H Thuesen; Allan Linneberg; Amalie S Ustrup; Signe Knag Pedersen; Charlotte Suppli Ulrik
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

Review 8.  European Respiratory Society International Congress 2018: four shades of epidemiology and tobacco control.

Authors:  Maaike de Vries; Eleanor L Axson; Jate Ratanachina; Orianne Dumas; Sara De Matteis; Annabelle Bédard; Célina Roda; Subhabrata Moitra; Elif Dagli; Athina Dimanti; Asli Gorek Dilektasli; Sofia Ravara; André F S Amaral
Journal:  ERJ Open Res       Date:  2019-03-04

9.  Supernormal lung function and risk of COPD: A contemporary population-based cohort study.

Authors:  Yunus Çolak; Børge G Nordestgaard; Peter Lange; Jørgen Vestbo; Shoaib Afzal
Journal:  EClinicalMedicine       Date:  2021-06-18

10.  Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Chin Kook Rhee; Yong Hyun Kim; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Hyoung Kyu Yoon; Sang Haak Lee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.